DrugPatentWatch Database Preview
Melphalan hydrochloride - Generic Drug Details
What are the generic sources for melphalan hydrochloride and what is the scope of freedom to operate?
Melphalan hydrochloride
is the generic ingredient in three branded drugs marketed by Apotex, Actavis Llc, Alvogen Inc, Dr Reddys Labs Ltd, Fresenius Kabi Usa, Gland Pharma Ltd, Ingenus Pharms Llc, Mylan Institutional, Par Sterile Products, Sagent Pharms Inc, Twi Pharms, Us Worldmeds Llc, West-ward Pharms Int, and Acrotech, and is included in sixteen NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Melphalan hydrochloride has seventy-one patent family members in seventeen countries.
There are twelve drug master file entries for melphalan hydrochloride. Thirteen suppliers are listed for this compound.
Summary for melphalan hydrochloride
| International Patents: | 71 |
| US Patents: | 4 |
| Tradenames: | 3 |
| Applicants: | 14 |
| NDAs: | 16 |
| Drug Master File Entries: | 12 |
| Suppliers / Packagers: | 13 |
| Bulk Api Vendors: | 15 |
| Clinical Trials: | 777 |
| Patent Applications: | 713 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for melphalan hydrochloride |
| DailyMed Link: | melphalan hydrochloride at DailyMed |
Recent Clinical Trials for melphalan hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Baptist Health South Florida | Phase 2 |
| Second Affiliated Hospital of Xi'an Jiaotong University | Early Phase 1 |
| 920th Hospital of Joint Logistics Support Force | Early Phase 1 |
Recent Litigation for melphalan hydrochloride
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA | 2019-05-23 |
| MERCK SHARP & DOHME CORP. v. MYLAN LABORATORIES LIMITED | 2018-03-29 |
| CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. | 2017-12-20 |
Pharmacology for melphalan hydrochloride
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
Synonyms for melphalan hydrochloride
| (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid;hydrochloride |
| (S)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanoic acid hydrochloride |
| 1VXP4V453T |
| 223M072 |
| 3223-07-2 |
| 4-[Bis(2-chloroethyl)-amino]-L-phenylalanine hydrochloride |
| 4-[bis(2-chloroethyl)-amino]-phenylalanine hydrochloride |
| AC-25549 |
| AI3-26377 |
| AKOS025401785 |
| Alanine Nitrogen Mustard |
| Alanine nitrogen mustard hydrochloride |
| ALANINE, 3-(p-(BIS(2-CHLOROETHYL)AMINO)PHENYL)-, MONOHYDROCHLORIDE, L- |
| Alkeran (GlaxoSmith) |
| ALKERAN (TN) |
| Alkeran hydrochloride |
| CB 3025 hydrochloride |
| CB-3025 HYDROCHLORIDE |
| CHEMBL1200863 |
| CTK8G0783 |
| D08173 |
| DTXSID60872785 |
| Evomela (TN) |
| FT-0773182 |
| L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine monohydrochloride |
| L-Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, hydrochloride |
| L-Alanine, hydrochloride |
| L-Phenylalanine mustard hydrochloride |
| L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-, monohydrochloride (9CI) |
| L-Phenylalanine, monohydrochloride |
| L-Sarcolysine hydrochloride |
| Melfalan hydrochloride |
| Melphalan HCl |
| NSC8806 |
| OUUYBRCCFUEMLH-YDALLXLXSA-N |
| Phenylalanine mustard hydrochloride |
| Q27252967 |
| SCHEMBL41335 |
| SK 15673 |
| UNII-1VXP4V453T |
| UNII-GEG3Q4FC64 component OUUYBRCCFUEMLH-YDALLXLXSA-N |
| WLN: QVYZ1R DN2G2G &GH |
Paragraph IV (Patent) Challenges for MELPHALAN HYDROCHLORIDE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| EVOMELA | POWDER;INTRAVENOUS | melphalan hydrochloride | 207155 | 2017-09-08 |
US Patents and Regulatory Information for melphalan hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Sterile Products | MELPHALAN HYDROCHLORIDE | melphalan hydrochloride | INJECTABLE;INJECTION | 204773-001 | Aug 22, 2016 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Actavis Llc | MELPHALAN HYDROCHLORIDE | melphalan hydrochloride | POWDER;INTRAVENOUS | 209323-001 | Mar 6, 2020 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Acrotech | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Sagent Pharms Inc | MELPHALAN HYDROCHLORIDE | melphalan hydrochloride | INJECTABLE;INJECTION | 201379-001 | Feb 28, 2017 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Apotex | ALKERAN | melphalan hydrochloride | INJECTABLE;INJECTION | 020207-001 | Nov 18, 1992 | AP | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for melphalan hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Apotex | ALKERAN | melphalan hydrochloride | INJECTABLE;INJECTION | 020207-001 | Nov 18, 1992 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for melphalan hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2016210707 | Start Trial |
| Eurasian Patent Organization | 201590617 | Start Trial |
| Japan | 2018052991 | Start Trial |
| Mexico | 2010004900 | Start Trial |
| European Patent Office | 2748205 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
